| Rawn Salenger, MD | |
|
7505 Osler Dr, Towson, MD 21204-7736 | |
| (410) 337-1783 | |
| Not Available |
| Full Name | Rawn Salenger |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 29 Years |
| Location | 7505 Osler Dr, Towson, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568465516 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna Of Maryland | Baltimore, MD | Home health agency |
| Home Call, Inc | Westminster, MD | Home health agency |
| Home Call - Frederick | Frederick, MD | Home health agency |
| University Of Md St Joseph Medical Center | Towson, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Maryland St Joseph Medical Group Llc | 4880846179 | 224 |
News Archive
Lifetime risks of developing Alzheimer's disease dementia vary considerably by age, gender and whether any signs or symptoms of dementia are present, according to a new study published online by Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.
› Verified 1 days ago
| Entity Name | University Of Maryland St Joseph Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770836785 PECOS PAC ID: 4880846179 Enrollment ID: O20121213000234 |
News Archive
Lifetime risks of developing Alzheimer's disease dementia vary considerably by age, gender and whether any signs or symptoms of dementia are present, according to a new study published online by Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rawn Salenger, MD 257 Lafayette Ave, Suite 330, Suffern, NY 10901-4830 Ph: (845) 368-8800 | Rawn Salenger, MD 7505 Osler Dr, Towson, MD 21204-7736 Ph: (410) 337-1783 |
News Archive
Lifetime risks of developing Alzheimer's disease dementia vary considerably by age, gender and whether any signs or symptoms of dementia are present, according to a new study published online by Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.
› Verified 1 days ago
Ali Akbar Najm Sadri, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 7505 Osler Dr, Suite 306, Towson, MD 21204 Phone: 410-296-2520 Fax: 410-821-6860 | |
Dr. R.c. Stewart Finney, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 7505 Osler Dr, Suite 512, Towson, MD 21204 Phone: 410-337-1783 |